Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 152

1.

Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia.

Braun TP, Okhovat M, Coblentz C, Carratt SA, Foley A, Schonrock Z, Smith BM, Nevonen K, Davis B, Garcia B, LaTocha D, Weeder BR, Grzadkowski MR, Estabrook JC, Manning HG, Watanabe-Smith K, Jeng S, Smith JL, Leonti AR, Ries RE, McWeeney S, Di Genua C, Drissen R, Nerlov C, Meshinchi S, Carbone L, Druker BJ, Maxson JE.

Nat Commun. 2019 Nov 29;10(1):5455. doi: 10.1038/s41467-019-13364-2.

2.

What do functional genomics tell us about pathogenesis of AML?

Tyner JW, Bottomly D, Wilmot B, McWeeney S.

Best Pract Res Clin Haematol. 2019 Dec;32(4):101101. doi: 10.1016/j.beha.2019.101101. Epub 2019 Oct 18. Review.

PMID:
31779979
3.

Acute myeloid leukemia-induced T-cell suppression can be reversed by inhibition of the MAPK pathway.

Moshofsky KB, Cho HJ, Wu G, Romine KA, Newman MT, Kosaka Y, McWeeney SK, Lind EF.

Blood Adv. 2019 Oct 22;3(20):3038-3051. doi: 10.1182/bloodadvances.2019000574.

4.

ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants.

Luo X, Feurstein S, Mohan S, Porter CC, Jackson SA, Keel S, Chicka M, Brown AL, Kesserwan C, Agarwal A, Luo M, Li Z, Ross JE, Baliakas P, Pineda-Alvarez D, DiNardo CD, Bertuch AA, Mehta N, Vulliamy T, Wang Y, Nichols KE, Malcovati L, Walsh MF, Rawlings LH, McWeeney SK, Soulier J, Raimbault A, Routbort MJ, Zhang L, Ryan G, Speck NA, Plon SE, Wu D, Godley LA.

Blood Adv. 2019 Oct 22;3(20):2962-2979. doi: 10.1182/bloodadvances.2019000644.

5.

Immune predictors of mortality following RNA virus infection.

Graham JB, Swarts JL, Menachery VD, Gralinski LE, Schäfer A, Plante KS, Morrison CR, Voss KM, Green R, Choonoo G, Jeng S, Miller DR, Mooney MA, McWeeney SK, Ferris MT, Pardo-Manuel de Villena F, Gale M, Heise MT, Baric RS, Lund JM.

J Infect Dis. 2019 Oct 17. pii: jiz531. doi: 10.1093/infdis/jiz531. [Epub ahead of print]

PMID:
31621854
6.

Illuminating biological pathways for drug targeting in head and neck squamous cell carcinoma.

Choonoo G, Blucher AS, Higgins S, Boardman M, Jeng S, Zheng C, Jacobs J, Anderson A, Chamberlin S, Evans N, Vigoda M, Cordier B, Tyner JW, Kulesz-Martin M, McWeeney SK, Laderas T.

PLoS One. 2019 Oct 9;14(10):e0223639. doi: 10.1371/journal.pone.0223639. eCollection 2019.

7.

Persistent Toll-like receptor 7 stimulation induces behavioral and molecular innate immune tolerance.

Michaelis KA, Norgard MA, Levasseur PR, Olson B, Burfeind KG, Buenafe AC, Zhu X, Jeng S, McWeeney SK, Marks DL.

Brain Behav Immun. 2019 Nov;82:338-353. doi: 10.1016/j.bbi.2019.09.004. Epub 2019 Sep 6.

8.

Visualization of drug target interactions in the contexts of pathways and networks with ReactomeFIViz.

Blucher AS, McWeeney SK, Stein L, Wu G.

F1000Res. 2019 Jun 20;8:908. doi: 10.12688/f1000research.19592.1. eCollection 2019.

9.

Genomic landscape of neutrophilic leukemias of ambiguous diagnosis.

Zhang H, Wilmot B, Bottomly D, Dao KT, Stevens E, Eide CA, Khanna V, Rofelty A, Savage S, Reister Schultz A, Long N, White L, Carlos A, Henson R, Lin C, Searles R, Collins RH, DeAngelo DJ, Deininger MW, Dunn T, Hein T, Luskin MR, Medeiros BC, Oh ST, Pollyea DA, Steensma DP, Stone RM, Druker BJ, McWeeney SK, Maxson JE, Gotlib JR, Tyner JW.

Blood. 2019 Sep 12;134(11):867-879. doi: 10.1182/blood.2019000611. Epub 2019 Jul 31.

PMID:
31366621
10.

Natural Product Target Network Reveals Potential for Cancer Combination Therapies.

Chamberlin SR, Blucher A, Wu G, Shinto L, Choonoo G, Kulesz-Martin M, McWeeney S.

Front Pharmacol. 2019 May 31;10:557. doi: 10.3389/fphar.2019.00557. eCollection 2019.

11.

Controlling for Contaminants in Low-Biomass 16S rRNA Gene Sequencing Experiments.

Karstens L, Asquith M, Davin S, Fair D, Gregory WT, Wolfe AJ, Braun J, McWeeney S.

mSystems. 2019 Jun 4;4(4). pii: e00290-19. doi: 10.1128/mSystems.00290-19.

12.

The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells.

Nechiporuk T, Kurtz SE, Nikolova O, Liu T, Jones CL, D'Alessandro A, Culp-Hill R, d'Almeida A, Joshi SK, Rosenberg M, Tognon CE, Danilov AV, Druker BJ, Chang BH, McWeeney SK, Tyner JW.

Cancer Discov. 2019 Jul;9(7):910-925. doi: 10.1158/2159-8290.CD-19-0125. Epub 2019 May 2.

PMID:
31048320
13.

Salt-sensitive transcriptome of isolated kidney distal tubule cells.

Swanson EA, Nelson JW, Jeng S, Erspamer KJ, Yang CL, McWeeney S, Ellison DH.

Physiol Genomics. 2019 Apr 1;51(4):125-135. doi: 10.1152/physiolgenomics.00119.2018. Epub 2019 Mar 15.

PMID:
30875275
14.

Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms.

Zhang H, Savage S, Schultz AR, Bottomly D, White L, Segerdell E, Wilmot B, McWeeney SK, Eide CA, Nechiporuk T, Carlos A, Henson R, Lin C, Searles R, Ho H, Lam YL, Sweat R, Follit C, Jain V, Lind E, Borthakur G, Garcia-Manero G, Ravandi F, Kantarjian HM, Cortes J, Collins R, Buelow DR, Baker SD, Druker BJ, Tyner JW.

Nat Commun. 2019 Jan 16;10(1):244. doi: 10.1038/s41467-018-08263-x.

15.

Predicting response to BET inhibitors using computational modeling: A BEAT AML project study.

Drusbosky LM, Vidva R, Gera S, Lakshminarayana AV, Shyamasundar VP, Agrawal AK, Talawdekar A, Abbasi T, Vali S, Tognon CE, Kurtz SE, Tyner JW, McWeeney SK, Druker BJ, Cogle CR.

Leuk Res. 2019 Feb;77:42-50. doi: 10.1016/j.leukres.2018.11.010. Epub 2019 Jan 7.

16.

CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells.

Edwards DK 5th, Watanabe-Smith K, Rofelty A, Damnernsawad A, Laderas T, Lamble A, Lind EF, Kaempf A, Mori M, Rosenberg M, d'Almeida A, Long N, Agarwal A, Sweeney DT, Loriaux M, McWeeney SK, Tyner JW.

Blood. 2019 Feb 7;133(6):588-599. doi: 10.1182/blood-2018-03-838946. Epub 2018 Nov 13.

PMID:
30425048
17.

Functional genomic landscape of acute myeloid leukaemia.

Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, Long N, Schultz AR, Traer E, Abel M, Agarwal A, Blucher A, Borate U, Bryant J, Burke R, Carlos A, Carpenter R, Carroll J, Chang BH, Coblentz C, d'Almeida A, Cook R, Danilov A, Dao KT, Degnin M, Devine D, Dibb J, Edwards DK 5th, Eide CA, English I, Glover J, Henson R, Ho H, Jemal A, Johnson K, Johnson R, Junio B, Kaempf A, Leonard J, Lin C, Liu SQ, Lo P, Loriaux MM, Luty S, Macey T, MacManiman J, Martinez J, Mori M, Nelson D, Nichols C, Peters J, Ramsdill J, Rofelty A, Schuff R, Searles R, Segerdell E, Smith RL, Spurgeon SE, Sweeney T, Thapa A, Visser C, Wagner J, Watanabe-Smith K, Werth K, Wolf J, White L, Yates A, Zhang H, Cogle CR, Collins RH, Connolly DC, Deininger MW, Drusbosky L, Hourigan CS, Jordan CT, Kropf P, Lin TL, Martinez ME, Medeiros BC, Pallapati RR, Pollyea DA, Swords RT, Watts JM, Weir SJ, Wiest DL, Winters RM, McWeeney SK, Druker BJ.

Nature. 2018 Oct;562(7728):526-531. doi: 10.1038/s41586-018-0623-z. Epub 2018 Oct 17.

18.

Community profiling of the urinary microbiota: considerations for low-biomass samples.

Karstens L, Asquith M, Caruso V, Rosenbaum JT, Fair DA, Braun J, Gregory WT, Nardos R, McWeeney SK.

Nat Rev Urol. 2018 Dec;15(12):735-749. doi: 10.1038/s41585-018-0104-z. Review.

19.

Cross-species molecular dissection across alcohol behavioral domains.

Farris SP, Riley BP, Williams RW, Mulligan MK, Miles MF, Lopez MF, Hitzemann R, Iancu OD, Colville A, Walter NAR, Darakjian P, Oberbeck DL, Daunais JB, Zheng CL, Searles RP, McWeeney SK, Grant KA, Mayfield RD.

Alcohol. 2018 Nov;72:19-31. doi: 10.1016/j.alcohol.2017.11.036. Epub 2017 Dec 6. Review.

20.

Regional Differences and Similarities in the Brain Transcriptome for Mice Selected for Ethanol Preference From HS-CC Founders.

Colville AM, Iancu OD, Lockwood DR, Darakjian P, McWeeney SK, Searles R, Zheng C, Hitzemann R.

Front Genet. 2018 Aug 28;9:300. doi: 10.3389/fgene.2018.00300. eCollection 2018.

Supplemental Content

Loading ...
Support Center